Overview

A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis

Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
Evaluation of safety, tolerability, PK and PD of ISIS 416858 in patients with end-stage renal disease (ESRD) receiving chronic hemodialysis.
Phase:
Phase 2
Details
Lead Sponsor:
Ionis Pharmaceuticals, Inc.
Collaborator:
Bayer